

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder

Protocol summary

Summary

Memory impairment is a common adverse effect of ECT. Current trial examines the effect of adjuvant treatment with Memantine on cognitive function of patients with major depressive disorder. There are two groups, one group receives ECT plus Memantine (20mg/day). The other group receives ECT. Mini mental status examination will be assessed at baseline, at the end of the last ECT session; and 2 weeks after the last session. Depression is assessed by Hamilton depression scale.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201506203930N38**
Registration date: **2016-07-01, 1395/04/11**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2016-07-01, 1395/04/11

Registrant information

Name

Ahmad Ghanizadeh

Name of organization / entity

Research Center for Psychiatry and Behavioral Sciences, Shiraz University Of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 71 1627 3070

Email address

ghanizad@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Shiraz University of Medical Sciences

Expected recruitment start date

2016-05-28, 1395/03/08

Expected recruitment end date

2017-06-21, 1396/03/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder

Public title

Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Aged between 18 to 65, both gender, major depressive disorder using DSM-IV criteria
Exclusion criteria: serious medical condition, hypothyroidism, bipolar mood disorder, pregnancy

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Shiraz University of Medical Sciences

Street address

Shiraz University of Medical Sciences

City

Fars

Postal code

--

Approval date

2016-01-25, 1394/11/05

Ethics committee reference number

IR.SUMS.MED.REC.1394.79

Health conditions studied**1****Description of health condition studied**

Major depressive disorder

ICD-10 code

F32

ICD-10 code description

Depressive episode

Primary outcomes**1****Description**

Depression Score

Timepoint

Baseline, the last session of ECT and 2 weeks after the last session of ECT

Method of measurement

Minimal status Examination

Secondary outcomes

empty

Intervention groups**1****Description**

Memantin (5mg/day) started and increase to 20mg/day

Category

Treatment - Drugs

2**Description**

Tablet

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Imam Reza Clinic

Full name of responsible person**Street address****City**

Shiraz

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shiraz University of Medical Sciences, Vice Chancellor for Research

Full name of responsible person

Seyed Basir Hashemi

Street address

Vice Chancellery for Research Affairs, Shiraz University of Medical Sciences department, Zand Blvd

City

Shiraz

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shiraz University of Medical Sciences, Vice Chancellor for Research

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Ali Sahraian

Position

Associate

Other areas of specialty/work**Street address**

Hafez hospital

City

Shiraz

Postal code

--

Phone

+98 71 3627 3070

Fax**Email**

sahraian@sums.ac.ir

Web page address

+98 71 3627 3070

Fax**Email**

ghanizad@sina.tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Ali Sahraian

Position

Associate professor of Psychiatry

Other areas of specialty/work**Street address**

Hafez Hospital

City

Shiraz

Postal code**Phone**

+98 71 3627 9319

Fax**Email****Web page address**

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Ahmad Ghanizadeh

Position

Professor of Psychiatry, Director of research center for psychiatry and behavioral sciences

Other areas of specialty/work**Street address**

Hafez hospital

City

Shiraz

Postal code

--

Phone

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty